Completed NA INTERVENTIONAL NCT00596479

Filgrastim for the Promotion of Collateral Growth in Patients With CAD

Subcutaneous Delivery of Filgrastim (rG-CSF) for the Promotion of Collateral Growth in Patients With Coronary Artery Disease

Sponsor: Insel Gruppe AG, University Hospital Bern

Conditions Coronary Artery Disease

Interventions Filgrastim (rG-CSF)

Updated 6 times since 2017 Last updated: Jun 15, 2015 Started: Nov 30, 2004 Primary completion: Dec 31, 2007 Completion: Dec 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Coronary Artery Disease, this trial is completed. The trial is conducted by Insel Gruppe AG, University Hospital Bern and has accumulated 6 data snapshots since 2004. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jul 2023 — Jul 2024 [monthly]

Completed NA
Jan 2021 — Jul 2023 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Nov 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Insel Gruppe AG, University Hospital Bern
Swiss Heart Foundation
Swiss National Science Foundation

Data source: Insel Gruppe AG, University Hospital Bern

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bern, Switzerland